How do you preserve muscle mass while losing weight on Ozempic, Wegovy, or Zepbound?

Why GLP-1s cause muscle loss

Evidence tier: 1 — STEP and SELECT trial body-composition substudies; ~25% lean-mass component is well-characterized in human GLP-1 RCTs.

Weight loss from any source — caloric restriction, GLP-1s, bariatric surgery — is rarely pure fat loss. The standard ratio in unsupported weight-loss interventions is approximately 75% fat / 25% lean mass, with the lean-mass component including muscle, bone density, and organ mass. GLP-1 trials show similar ratios when patients aren't actively training to preserve lean mass.

The mechanism isn't unique to GLP-1s. The body responds to caloric deficit by reducing energy demand, which includes catabolizing some lean tissue. The faster the weight loss and the larger the deficit, the more pronounced the lean-mass component. GLP-1s drive substantial deficits (often 500-800 kcal/day reductions in food intake), so the effect is meaningful.

Why this matters: lean mass is the largest predictor of resting metabolic rate. Lose 10kg with 25% as lean mass and you've lost ~2.5kg of muscle plus bone density, and your maintenance calorie requirement drops more than your scale weight implies. This is the mechanism behind the post-GLP-1 regain pattern — patients re-feed at pre-loss caloric levels into a body with reduced metabolic capacity.

What works to preserve lean mass during weight loss

Evidence tier: 1 — Resistance training, protein, sleep, and rate-of-loss interventions all supported by RCTs (Nedeltcheva 2010 + replications).

The evidence-based interventions, in approximate order of impact:

1. Resistance training, twice weekly minimum. This is the single highest-leverage intervention. Two full-body resistance sessions per week during active weight loss reduces lean mass loss from ~25% of total to ~5-10%. Bodyweight is fine to start; progressive overload matters more than equipment.

2. Adequate protein intake (1.6-2.2 g/kg body weight). GLP-1 patients often eat substantially less total food, which makes hitting protein targets harder. Protein-prioritized eating patterns (protein first, fiber second, everything else after) preserve more lean mass than equal-calorie low-protein diets.

3. Slower weight loss rate (≤1% body weight per week). Faster loss compounds lean-mass loss. The Wegovy/Zepbound dose escalation isn't optional; the gradual approach exists for tolerability and lean-mass preservation reasons.

4. Sleep ≥7 hours. Sleep deprivation during weight loss biases the lean-mass-vs-fat-mass ratio toward more lean loss (Nedeltcheva et al. 2010 and replications).

These four together can essentially eliminate the lean-mass loss problem at standard GLP-1 doses. They're also the same interventions that improve every other metabolic outcome. Peptide adjuncts are downstream of these, not substitutes for them.

Where Tesamorelin fits

Evidence tier: 2 — Tesamorelin HIV-VAT RCTs (Falutz 2007, Stanley 2012); GLP-1 combination use is mechanistic extrapolation, not RCT-supported.

Tesamorelin is a 44-amino-acid GHRH (growth hormone releasing hormone) analog FDA-approved as Egrifta for HIV-associated visceral adipose tissue reduction. The off-label rationale for GLP-1 muscle-preservation use:

• Endogenous GH/IGF-1 elevation supports lean mass synthesis pathways
• Targeted reduction of visceral adipose tissue specifically (not subcutaneous fat)
• 12-month tolerability and safety data from HIV indication
• Daily subcutaneous dosing (no weekly injection burden on top of GLP-1)
• Doesn't suppress endogenous GH like exogenous HGH would

The supporting evidence for the GLP-1 + Tesamorelin combination specifically is thin — there are no published RCTs of the combination as a muscle-preservation protocol. The use case is mechanistic extrapolation: GLP-1 drives weight loss that includes lean component, Tesamorelin supports lean mass synthesis via endogenous GH axis, the combination plausibly preserves more lean mass than GLP-1 alone.

Standard protocol when used as GLP-1 adjunct: Tesamorelin 1-2mg subcutaneously daily, started either at GLP-1 initiation (proactive) or at 8-12 weeks into the GLP-1 protocol (reactive, after lean mass loss is detected via DEXA). Continue throughout active weight loss, taper off when patient transitions to maintenance dose.

Read the full Tesamorelin fact box →

Where AOD-9604 doesn't fit

Evidence tier: 2 — Multiple Phase 2b RCTs failed to show efficacy as monotherapy; lean-mass preservation use unsupported by trial data.

AOD-9604 is the modified C-terminal fragment (residues 176-191) of human growth hormone. Marketed as a fat-loss peptide that doesn't elevate IGF-1. Multiple Phase 2b trials failed to show meaningful weight loss as monotherapy versus placebo.

The 2026 community use of AOD-9604 as a GLP-1 muscle-sparing adjunct is largely unsupported by clinical evidence. The mechanistic rationale (lipolytic without growth signaling) doesn't translate into measurable lean-mass preservation in trials. We document AOD-9604 because patients ask about it; we don't recommend it as a Tesamorelin substitute.

If your prescriber has experience with AOD-9604 in this specific use case and clinical reasoning for selecting it, that's a different conversation. As a default community-protocol choice, the evidence doesn't support it.

Read the AOD-9604 fact box →

When to add a peptide adjunct vs when to optimize the basics

Evidence tier: 5 — Editorial patient-selection framework; integrates Tier-1 basics with Tier-2 adjunct evidence into a decision rule.

Reasonable to add Tesamorelin or similar adjunct:

• DEXA scan at 8-12 weeks shows ≥20% of weight loss is lean mass despite resistance training
• Patient with sarcopenic obesity (low muscle mass to start) where any additional loss is clinically problematic
• Patient on GLP-1 for cardiometabolic indication where visceral fat reduction is the primary goal
• Older patients (>65) where lean-mass preservation timeline matters more
• Patient with adequate financial flexibility (~$300-500/month for compounded Tesamorelin)

Reasonable to skip the adjunct and focus on basics:

• Patient hitting protein and resistance-training targets without DEXA evidence of disproportionate lean loss
• Younger patients (<45) with significant fat reserve
• Cost-constrained patients where the marginal lean-mass preservation isn't worth $300-500/month
• Patients in dose-escalation phase of GLP-1 — wait until maintenance to assess the lean-mass picture
• Patients without baseline body composition data — measure first

The most common mistake is adding peptide adjuncts before optimizing the resistance training, protein, and sleep foundations. The peptides aren't a substitute. They're a small addition on top of those.

DEXA scans matter

Evidence tier: 2 — DEXA is the validated reference standard for body composition assessment; widely cited in GLP-1 substudies and sports-medicine literature.

The single most useful tool for assessing whether your GLP-1 weight loss is preserving lean mass is a DEXA scan. Two scans — baseline before GLP-1 initiation, then 16-20 weeks into the protocol — show the body composition change clearly. Without DEXA you're guessing.

DEXA costs $100-300 per scan in most US markets, available at private body-composition clinics and increasingly at orthopedic imaging centers. InBody scales (multifrequency BIA) are a cheaper alternative but with meaningfully lower accuracy for absolute body composition; useful for trend monitoring only.

If your prescriber doesn't already integrate body composition assessment into the protocol, request it. Without measurement, "muscle preservation" is just a vibe.

The cleanest 2026 stack

Evidence tier: 5 — Editorial protocol synthesis combining Tier-1 lifestyle interventions with Tier-2 Tesamorelin adjunct rationale.

For a patient who wants to maximize lean-mass preservation during GLP-1 weight loss:

• Wegovy/Zepbound at standard escalation (don't speed-rush)
• Resistance training 2-3×/week, full body, progressive overload
• Protein 1.8-2.2 g/kg target, prioritized in meal structure
• Sleep ≥7 hours nightly
• DEXA at baseline and every 16 weeks
• Tesamorelin 1-2mg/day SC if DEXA shows >20% lean component despite the basics, or proactively in higher-risk patients (older, sarcopenic baseline)
• Avoid AOD-9604 as a default unless your prescriber has specific reasoning

This is not original — it's standard sports-medicine practice applied to a GLP-1 weight-loss context. The peptide adjunct is the smallest piece. The basics do most of the work.

What we'll be tracking

Evidence tier: 5 — Editorial maintenance commitment; no clinical evidence claim made.

Article updates when: - Published RCT data emerges on GLP-1 + Tesamorelin combination - New muscle-sparing peptide candidates with credible Phase 2/3 data - Updated body-composition data from longer GLP-1 follow-up cohorts - DEXA accessibility/cost changes affecting the measurement piece of the protocol

For ongoing context, see GLP-1 tapering for the maintenance-phase discussion and Tesamorelin for the molecule-level detail.

References

• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
• Falutz J, Allas S, Blot K, et al. 2007. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. PMID 18057338
• Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. 2012. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. PMID 22495074
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131

Limitations

This protocol does not apply to patients with active or recent malignancy (Tesamorelin's IGF-1 elevation is a relative contraindication for several oncologic histologies), patients with diabetic retinopathy (GH-axis stimulation is precautionary in this population), pregnant or nursing patients, patients with uncontrolled type 2 diabetes, or anyone with a history of pituitary disease. Tesamorelin should also be avoided in patients with severe renal or hepatic impairment without specialist supervision, and patients with documented hypersensitivity to mannitol-containing formulations.

The cited evidence cannot tell us whether the GLP-1 plus Tesamorelin combination preserves a clinically meaningful additional fraction of lean mass over GLP-1 plus resistance training alone, what the long-term cardiometabolic effect of sustained Tesamorelin use is in non-HIV populations, or how the combination performs in patients over 70. The retatrutide-class agents may shift the lean-mass picture again once mature data lands.

We would change our framing on three signals: a published RCT of GLP-1 plus Tesamorelin with DEXA endpoints, FDA action on Tesamorelin's compounding status, or new lean-mass-sparing data from the dual- and tri-agonist class.